Clinical Trial: A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07082686) titled 'A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma' on July 15.

Brief Summary: This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.

Study Start Date: July 18

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Intervention: DRUG: ICP-248

Eligible patients will receive ICP-248 orally as per the protocol

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Disclaimer: Curated ...